Literature DB >> 20676124

Therapy: Challenging the course of RA: time for drug-free remission?

Daniel Aletaha.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20676124     DOI： 10.1038/nrrheum.2010.101

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  8 in total

1.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.

Authors:  Mark A Quinn; Philip G Conaghan; Philip J O'Connor; Zunaid Karim; Adam Greenstein; Andrew Brown; Clare Brown; Alexander Fraser; Stephen Jarret; Paul Emery
Journal:  Arthritis Rheum       Date:  2005-01

2.  Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.

Authors:  J S Smolen; C Han; D M F M van der Heijde; P Emery; J M Bathon; E Keystone; R N Maini; J R Kalden; D Aletaha; D Baker; J Han; M Bala; E W St Clair
Journal:  Ann Rheum Dis       Date:  2008-07-01       Impact factor: 19.103

3.  Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.

Authors:  Gisela Kobelt; Linus Jönsson; Peter Lindgren; Adam Young; Kerstin Eberhardt
Journal:  Arthritis Rheum       Date:  2002-09

4.  Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.

Authors:  S ten Wolde; F C Breedveld; J Hermans; J P Vandenbroucke; M A van de Laar; H M Markusse; M Janssen; H R van den Brink; B A Dijkmans
Journal:  Lancet       Date:  1996-02-10       Impact factor: 79.321

5.  Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis.

Authors:  Olivier Brocq; Elodie Millasseau; Christine Albert; Christian Grisot; Philippe Flory; Christian-Hubert Roux; Liana Euller-Ziegler
Journal:  Joint Bone Spine       Date:  2009-04-11       Impact factor: 4.929

6.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2008-02

7.  Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study.

Authors:  Y Tanaka; T Takeuchi; T Mimori; K Saito; M Nawata; H Kameda; T Nojima; N Miyasaka; T Koike
Journal:  Ann Rheum Dis       Date:  2010-04-01       Impact factor: 19.103

8.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103
  8 in total
  1 in total

1.  Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

Authors:  Lise M Verhoef; Bart Jf van den Bemt; Aatke van der Maas; Johanna E Vriezekolk; Marlies E Hulscher; Frank Hj van den Hoogen; Wilco Ch Jacobs; Noortje van Herwaarden; Alfons A den Broeder
Journal:  Cochrane Database Syst Rev       Date:  2019-05-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.